| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M J Cronin, A Reches, R M MacLeod, I S Logi. Tumors producing chronic hyperprolactinemia do not alter [3H]spiperone binding and dopamine turnover in the corpus striatum of the female rat. European journal of pharmacology. vol 91. issue 2-3. 1983-11-23. PMID:6617744. |
tumors producing chronic hyperprolactinemia do not alter [3h]spiperone binding and dopamine turnover in the corpus striatum of the female rat. |
1983-11-23 |
2023-08-12 |
rat |
| P L Canonico, C A Valdenegro, R M MacLeo. The inhibition of phosphatidylinositol turnover: a possible postreceptor mechanism for the prolactin secretion-inhibiting effect of dopamine. Endocrinology. vol 113. issue 1. 1983-08-11. PMID:6861715. |
in rats bearing the transplantable prl-secreting tumor mttw15, the hyperprolactinemia produced by the tumor stimulates hypothalamic turnover of dopamine, with a consequent inhibition of pituitary gland prl secretion. |
1983-08-11 |
2023-08-12 |
rat |
| C B Webb, J L Thominet, H Barowsky, M Berelowitz, L A Frohma. Evidence for lactotroph dopamine resistance in idiopathic hyperprolactinemia. The Journal of clinical endocrinology and metabolism. vol 56. issue 6. 1983-06-23. PMID:6841551. |
evidence for lactotroph dopamine resistance in idiopathic hyperprolactinemia. |
1983-06-23 |
2023-08-12 |
Not clear |
| C B Webb, J L Thominet, H Barowsky, M Berelowitz, L A Frohma. Evidence for lactotroph dopamine resistance in idiopathic hyperprolactinemia. The Journal of clinical endocrinology and metabolism. vol 56. issue 6. 1983-06-23. PMID:6841551. |
previous studies in patients with idiopathic hyperprolactinemia (ih) that have suggested the presence of decreased central dopaminergic tone have assumed normal responsiveness of lactotrophs to dopamine (da). |
1983-06-23 |
2023-08-12 |
Not clear |
| E E Müller, A R Genazzani, S Murr. Nomifensine: diagnostic test in hyperprolactinemic states. The Journal of clinical endocrinology and metabolism. vol 47. issue 6. 1983-06-17. PMID:263356. |
nomifensine, an antidepressant agent which activates dopamine (d) neurotransmission mainly by inhibiting da reuptake in the central nervous system, was administered either to puerperal lactating women or to subjects with nonpuerperal hyperprolactinemia. |
1983-06-17 |
2023-08-11 |
human |
| K Y Ho, G A Smythe, L Lazaru. Prolactin response to dopamine synthesis inhibition using monoiodotyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia. The Journal of clinical endocrinology and metabolism. vol 56. issue 4. 1983-05-05. PMID:6833458. |
prolactin response to dopamine synthesis inhibition using monoiodotyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia. |
1983-05-05 |
2023-08-12 |
human |
| R W Fuller, J A Clemens, M D Hyne. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia. Journal of clinical psychopharmacology. vol 2. issue 6. 1983-02-25. PMID:7174859. |
pergolide mesylate is a potent dopamine agonist that is being evaluated clinically in parkinson disease, hyperprolactinemia, and other diseases. |
1983-02-25 |
2023-08-12 |
human |
| V De Leo, C Massafra, S La Marca, M De Leo, C Venturi, T M Urbani, A R Genazzan. [Indirect dopamine agonists and direct dopamine antagonists in the diagnosis of hyperprolactinemia]. Bollettino della Societa italiana di biologia sperimentale. vol 58. issue 16. 1983-01-07. PMID:7138672. |
[indirect dopamine agonists and direct dopamine antagonists in the diagnosis of hyperprolactinemia]. |
1983-01-07 |
2023-08-12 |
Not clear |
| A Barbarino, L De Marinis, C Anile, E Menini, G Merlini, G Mair. Dopaminergic mechanisms regulating prolactin secretion in patients with prolactin-secreting pituitary adenoma. Long-term studies after selective transsphenoidal surgery. Metabolism: clinical and experimental. vol 31. issue 11. 1982-12-18. PMID:6813636. |
these results suggest that: 1) hyperprolactinemia induced by "autonomous" pituitary adenomas increases hypothalamic dopamine (da) secretion, which in turn inhibits prl secretion by nonadenomatous lactotropes. |
1982-12-18 |
2023-08-12 |
Not clear |
| C Ferrari, P Rampini, R Benco, R Caldara, C Scarduelli, P G Crosignan. Functional characterization of hypothalamic hyperprolactinemia. The Journal of clinical endocrinology and metabolism. vol 55. issue 5. 1982-12-03. PMID:6811605. |
these data suggest that the mild to moderate hyperprolactinemia found in many patients with hypothalamic lesions is due to dopamine deficiency at the pituitary level, that trh and dopamine receptors at the lactotropes are intact in this condition, and that paired trh and sulpiride tests may be of some diagnostic utility in hyperprolactinemic patients. |
1982-12-03 |
2023-08-12 |
human |
| J W Simpkins, C A Hodson, P S Kalra, S P Kalr. Chronic hyperprolactinemia depletes hypothalamic dopamine concentrations in male rats. Life sciences. vol 30. issue 16. 1982-08-07. PMID:7087668. |
chronic hyperprolactinemia depletes hypothalamic dopamine concentrations in male rats. |
1982-08-07 |
2023-08-12 |
rat |
| S Ruggieri, P Falaschi, M Baldassarre, R D'Urso, G De Giorgio, A Rocco, A Agnol. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease. Neuropsychobiology. vol 8. issue 2. 1982-06-14. PMID:7070643. |
the data gathered indicate that benserazide-induced hyperprolactinemia in parkinsonian patients could be due to a direct effect of the drug at the hypothalamic level and consequently to an inhibition of dopamine decarboxylation in the tuberoinfundibular dopaminergic system. |
1982-06-14 |
2023-08-12 |
rat |
| A G Bauer, W J de Greef, F H de Jong, J H Wilson, S W Lambert. hyperprolactinemia of portal hypertension in rats. Gastroenterology. vol 82. issue 2. 1982-03-26. PMID:7054021. |
the hyperprolactinemia of portal hypertension is probably caused by elevated estrogen levels which interfere with hypothalamic dopamine release. |
1982-03-26 |
2023-08-12 |
rat |
| R L Perryman, A D Rogol, D L Kaiser, R M MacLeod, M O Thorne. Pergolide mesylate: its effects on circulating anterior pituitary hormones in man. The Journal of clinical endocrinology and metabolism. vol 53. issue 4. 1981-12-21. PMID:6793609. |
pergolide is a potent dopamine agonist with the anticipated endocrine profile and clinical effects; its long duration of actions offers promise of single daily dose therapy for hyperprolactinemia. |
1981-12-21 |
2023-08-12 |
human |
| P Contreras, G Generini, H Michelsen, H Pumarino, C Campin. Hyperprolactinemia and galactorrhea: spontaneous versus iatrogenic hypothyroidism. The Journal of clinical endocrinology and metabolism. vol 53. issue 5. 1981-12-21. PMID:7197286. |
these data indicate that in primary hypothyroidism 1) the duration of illness is important in the development of hyperprolactinemia, 2) galactorrhea is more common in young women with spontaneous disease and high prl levels, and 3) hypothalamic dopamine appears reduced in spontaneous disease. |
1981-12-21 |
2023-08-12 |
Not clear |
| P S Kalra, J W Simpkins, S P Kalr. Hyperprolactinemia counteracts the testosterone-induced inhibition of the preoptic area dopamine turnover. Neuroendocrinology. vol 33. issue 2. 1981-10-25. PMID:6115329. |
hyperprolactinemia counteracts the testosterone-induced inhibition of the preoptic area dopamine turnover. |
1981-10-25 |
2023-08-12 |
rat |
| P S Kalra, J W Simpkins, S P Kalr. Hyperprolactinemia counteracts the testosterone-induced inhibition of the preoptic area dopamine turnover. Neuroendocrinology. vol 33. issue 2. 1981-10-25. PMID:6115329. |
the present study was undertake to determine the effects of hyperprolactinemia on dopamine (da) concentrations and turnover rates in the medial basal hypothalamus (mbh) and the preoptic area-suprachiasmatic nucleus region (poa-scn) in castrated and castrated, testosterone(t) implanted male rats. |
1981-10-25 |
2023-08-12 |
rat |
| G Verde, P G Chiodini, A Liuzzi, R Cozzi, F Favales, L Botalla, B Spelta, D Dalla Bonzana, E Rainer, R Horowsk. Effectiveness of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states. Journal of endocrinological investigation. vol 3. issue 4. 1981-05-21. PMID:6782153. |
we have studied the effects of the chronic administration of the dopamine agonist lisuride (l) in 21 acromegalics (group 1) and in 25 patients with pathological hyperprolactinemia (group 2). |
1981-05-21 |
2023-08-12 |
Not clear |
| F Massara, A R Genazzani, F Camanni, V De Leo, G M Molinatti, E E Mülle. Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone. Fertility and sterility. vol 35. issue 2. 1981-05-13. PMID:7202740. |
forty-one subjects with hyperprolactinemia underwent testing on separate occasions with nomifensine, an indirectly acting dopamine agonist, and domperidone, a dopamine receptor-blocking agent. |
1981-05-13 |
2023-08-12 |
human |
| T Ogihara, A Maruyama, T Naka, J Higaki, T Kanda, M Goto, T Onishi, Y Kumahar. Is normoreninemic essential hypertension caused by disordered central dopaminergic regulation? Clinical and experimental hypertension. vol 2. issue 1. 1980-12-18. PMID:6774864. |
some investigators have reported that plasma prolactin levels are elevated in hypertensive men and that both their hyperprolactinemia and hypertension were controlled by bromocriptine, a dopamine agonist. |
1980-12-18 |
2023-08-12 |
Not clear |